Advaxis, Inc. (NASDAQ:ADXS) shares gapped up prior to trading on Thursday . The stock had previously closed at $0.43, but opened at $0.43. Advaxis shares last traded at $0.42, with a volume of 27,077 shares.

ADXS has been the subject of several research analyst reports. ValuEngine raised shares of Advaxis from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright reissued a “neutral” rating on shares of Advaxis in a research report on Wednesday, June 12th. Finally, Zacks Investment Research raised shares of Advaxis from a “sell” rating to a “hold” rating in a research report on Friday, August 9th.

The company’s 50-day moving average price is $1.13 and its two-hundred day moving average price is $1.89. The company has a market cap of $7.09 million, a P/E ratio of -0.02 and a beta of 3.23.

Advaxis (NASDAQ:ADXS) last released its earnings results on Monday, June 10th. The biotechnology company reported ($1.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($0.13). The company had revenue of $1.19 million during the quarter, compared to the consensus estimate of $0.34 million. Advaxis had a negative return on equity of 86.88% and a negative net margin of 126.12%. As a group, analysts forecast that Advaxis, Inc. will post -2.7 EPS for the current year.

Large investors have recently made changes to their positions in the stock. Two Sigma Investments LP grew its position in shares of Advaxis by 2,468.2% during the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 355,415 shares during the last quarter. Deutsche Bank AG grew its position in shares of Advaxis by 5,970.3% during the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 553,031 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Advaxis by 53,633.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 51,047 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 50,952 shares during the last quarter. BlackRock Inc. grew its position in shares of Advaxis by 3.1% during the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 43,368 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Advaxis by 71.1% during the 2nd quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock valued at $481,000 after buying an additional 95,607 shares during the last quarter. 7.78% of the stock is owned by institutional investors and hedge funds.

About Advaxis (NASDAQ:ADXS)

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Story: Quantitative Easing

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.